Skip to content

Eiger BioPharma started at buy, target $32, by BTIG

July 14, 2017

BTIG initiates coverage on Eiger BioPharma (NASDAQ: EIGR) with a Buy rating and a price target of $32.00.

Analyst Robert Hazlett likes the company’s development of promising novel solutions for rare diseases. He comments “Eiger develops novel therapeutics for orphan diseases. It has four significant assets in Phase 2 for four distinct orphan indications. Lonafarnib, an oral prenylation inhibitor, and PEG interferon lambda are being developed for hepatitis delta virus (HDV), the cause of the most severe form of viral hepatitis. Exendin 9-39, a GLP-1 antagonist, has reduced symptoms of severe hypoglycemia associated with bariatric surgeries. Ubenimex, an LTB4 inhibitor, is being developed for pulmonary arterial hypertension and lymphedema.”


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: